Is JNJ stock a Buy, Sell, or Hold?

Based on our analysis, JNJ is currently a WAIT with low confidence. 📊 MIXED SIGNALS: JNJ shows conflicting indicators. Wait for confirmation before entering.

What is the fair value of JNJ stock?

Our analysis estimates the fair value range for JNJ to be between $264.29 and $273.20. The current price is $256.03.

What is the analyst price target for JNJ?

The average Wall Street analyst price target for JNJ is $279.27. This implies a potential upside of 9.1% from current levels.

Johnson & Johnson (JNJ) Stock: Buy, Sell, or Hold?

JNJ - Johnson & Johnson

PHARMACEUTICAL PREPARATIONS

$256.03

-2.63 (-1.02%) ▼

5d: -5.6%

30d: -6.97%

90d: -1.27%

WAIT

LOW Confidence

Protect Your JNJ Gains

Analysis Updated: Oct 2, 2026 12:00 AM ET

Earnings: Oct 13, 2026 9d

Smart Money Accumulation

Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →

Signal fired Oct 2, 2026 at $256.03 · last confirmed Oct 2, 2026

Strength: 7.6/10

Get Alerted When JNJ Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 MIXED SIGNALS: JNJ shows conflicting indicators. Wait for confirmation before entering.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 8.3%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$311.87

Based on 6.2% avg growth

INTRINSIC VALUE TODAY

$193.65

Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.3x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: JNJ is currently trading at $256.03, which is considered oversold relative to its 30-day fair value range of $264.29 to $273.20. From a valuation perspective, the stock is trading at a premium (Forward PE: 21.3) compared to its historical average (19.3). At these levels, the market is pricing in 3.4% annual earnings growth.

Technical Outlook: Technically, JNJ is in a strong uptrend. The price is currently testing key support at $255.12. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position OVERSOLD

Historical Trading Range $264.29 - $273.20

Company Quality Score 52/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 78.1%

Protect Your Profits

Holding JNJ? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

BULLISH: Price oversold vs 30-day range
NEUTRAL: Mixed technical signals (44/100)
BULLISH: High volume confirmation
NEUTRAL: Near Wall St target ($279.27)
BULLISH: Expecting earnings turnaround to 3.4% growth with 6.6% revenue growth
WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $264.29 - $273.20

Current vs Trading Range OVERSOLD

Support & Resistance Levels

Support Level $255.12

Resistance Level $275.23

Current Trend Strong Uptrend

Technical data as of Oct 2, 2026

Fundamental Context

Forward P/E (Next Year Est.) 21.34

Wall Street Target $279.27 (+9.1%)

Revenue Growth (YoY) 6.6%

Earnings Growth (YoY) -0.9%

Profit Margin 21.5%

Valuation Premium vs History +3.4% premium

PE vs Historical 21.3 vs 19.3 FAIR

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): +3.4% (market-implied from PE analysis)

1-Year Target $264.74 (+3%)

2-Year Target $273.74 (+7%)

3-Year Target $283.04 (+11%)

3-Yr Target (if PE normalizes) (PE: 21→19) PE COMPRESSION $255.95 (0%)

Earnings growth offset by PE compression

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 21.3, Growth: 8.3%) $324.86 (+27%)

Base: (SPY PE: 20.4, Growth: 8.3%) $310.51 (+21%)

Bear: (PE: 17.3, Growth: 8.3%) $263.94 (+3%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (31x PE), but valuation improves significantly next year (21x PE) as earnings recover.

Trailing PE: 30.68 | Current EPS (TTM): $8.43

Bull Case $404.89 (+58%)

Analyst growth 42.3%, PE expands to 33.8

Base Case $368.08 (+44%)

Market implied 42.3%, PE stable at 30.7

Bear Case $175.89 (-31%)

Severe decline -20.0%, PE contracts to 26.1

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: October 02, 2026 10:20 PM ET
Data refreshes hourly during market hours. Next update: 11:20 PM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is JNJ showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

NEUTRAL

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for JNJ.

Create Free Account

Already have an account? Log In

Featured in Portfolios

JNJ is a key holding in these high-performance investment strategies.

Healthcare Giants Sector • +16.6% Return

Dividend Aristocrats Income • +8.1% Return

View All Strategies

Top Rated Drug Manufacturers - General Stocks

Top-rated stocks in Drug Manufacturers - General by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
LLY Eli Lilly and Company	STRONG BUY 31 analysts	$1325	48 HOLD
GILD Gilead Sciences Inc	BUY 30 analysts	$159	46 HOLD
ABBV AbbVie Inc	BUY 28 analysts	$279	57 HOLD
AMGN Amgen Inc	HOLD 32 analysts	$389	55 HOLD
BIIB Biogen Inc	HOLD 37 analysts	$238	48 HOLD

LLY Eli Lilly and Com…

48 HOLD

GILD Gilead Sciences I…

Advanced JNJ Option Strategies

Professional options setups generated by AI based on today's JNJ price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for JNJ

JNJ Technical Chart JNJ Price Prediction JNJ Earnings Date JNJ Investment Advisor JNJ Fair Price Analyzer JNJ Options Advisor JNJ Options Chain JNJ Options Analysis JNJ Competitors

Compare JNJ with Peers

JNJ vs PG
Which one to buy?

JNJ vs PFE
Which one to buy?

JNJ vs MRK
Which one to buy?

JNJ vs KO
Which one to buy?

JNJ vs XOM
Which one to buy?

JNJ vs UTHR
Winner: JNJ

JNJ vs LEXX

BFRI vs JNJ

CTMX vs JNJ

RAPP vs JNJ
Winner: JNJ

Create New Comparison View All Competitors

Tradestie